Insider Selling: Medpace (NASDAQ:MEDP) CFO Sells 3,000 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CFO Kevin Brady sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Medpace Price Performance

Shares of MEDP stock traded down $6.68 during mid-day trading on Tuesday, hitting $611.81. The company had a trading volume of 352,084 shares, compared to its average volume of 412,556. The company has a market capitalization of $17.23 billion, a P/E ratio of 42.78, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $626.26. The stock’s 50 day moving average price is $551.90 and its 200-day moving average price is $436.91.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter in the previous year, the business posted $3.01 earnings per share. The business’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on MEDP shares. TD Cowen upped their price objective on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. Rothschild & Co Redburn lowered shares of Medpace from a “buy” rating to a “neutral” rating and upped their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays upped their target price on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday, October 24th. Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th. Finally, Truist Financial set a $555.00 price objective on Medpace in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $487.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. purchased a new stake in Medpace during the third quarter worth approximately $283,000. Ariadne Wealth Management LP acquired a new stake in Medpace during the 3rd quarter worth $244,000. Wilmington Savings Fund Society FSB raised its stake in Medpace by 124.1% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock worth $67,000 after acquiring an additional 72 shares in the last quarter. Caerus Investment Advisors LLC purchased a new stake in Medpace in the third quarter valued at $811,000. Finally, Sunbelt Securities Inc. boosted its stake in Medpace by 12.3% in the third quarter. Sunbelt Securities Inc. now owns 464 shares of the company’s stock valued at $239,000 after acquiring an additional 51 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.